CAS: 2247236-59-3

BY27 is an innovative synthetic derivative, designed as a specialized compound for advanced biochemical applications. This product is derived from a unique sequence of engineered organic compounds, developed through a process of targeted molecular synthesis. Its primary mode of action is the selective modulation of specific biochemical pathways, achieved through high-affinity interaction with targeted molecular structures. This allows for precise manipulations within cellular systems, facilitating the study of complex biological processes. BY27 is primarily used in laboratory settings for investigative research, particularly in the fields of molecular biology and pharmacology. Its applications extend to studying cellular responses, protein interactions, and the elucidation of gene expression patterns. The product's high specificity and efficacy make it an indispensable tool for experimental protocols involving mechanistic investigations and hypothesis-driven research. Researchers employ BY27 to gain insights into cellular dynamics, advancing our understanding of fundamental biological phenomena.

BY27 is a BET BD2 inhibitor with anticancer activity that inhibits BRD2, BRD3 and BRD4 and suppresses tumor growth.

BY27